Tscan Therapeutics Inc TCRX

$0.32 +0.00 (0.94%)

Valuation

Market cap
21,520,000
Revenue TTM
$10,330,000
Net income TTM
$-129,770,000
PE ratio
0.00
Forward PE
—
Profit margin
-1,256.24%
Debt to equity
0.47

Trading

Volume
151,900
Avg volume
794,242
Day's range
$0.32 – $0.33
Shares out
67,779,000
Stochastic %K
16%
Beta
1.15
Analysts
Sell
Price target
$2.67

Price

Company profile

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell t...

Show more

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
857 399 9500
Website
https://www.tscan.com
Address
830 Winter Street, Waltham, United States

Latest news

Stocktwits

SaladMan00 Oct 2, 7:07 PM
$TCRX sub 0.30 and I am adding
0 replies
focafoca99 Sep 30, 9:15 PM
$TCRX reveals CFO and CMO departures with lump-sum cash awards of $85K and $125K under separation agreements.
0 replies
SaladMan00 Sep 30, 7:05 PM
$TCRX anyone who is bullish on this deserves to have an asteroid to their head
0 replies
SaladMan00 Sep 30, 12:42 PM
$TCRX scam and trash and useless stock. If you bought shares and are bullish you deserve to be atomised
0 replies
SaladMan00 Sep 30, 1:08 AM
$TCRX trash stock but I am buying if it dips below 0.30
0 replies
SaladMan00 Sep 29, 10:00 PM
$TCRX horrible stock
0 replies
SaladMan00 Sep 29, 9:31 PM
$TCRX trash stock
0 replies
SaladMan00 Sep 29, 6:39 PM
$TCRX if you don’t buy this dip, you hate money
1 replies